CN120022352A - Cxcr3的可切割激活剂及其使用方法 - Google Patents

Cxcr3的可切割激活剂及其使用方法 Download PDF

Info

Publication number
CN120022352A
CN120022352A CN202510050400.1A CN202510050400A CN120022352A CN 120022352 A CN120022352 A CN 120022352A CN 202510050400 A CN202510050400 A CN 202510050400A CN 120022352 A CN120022352 A CN 120022352A
Authority
CN
China
Prior art keywords
peptide
cxcl
seq
amino acid
cathepsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510050400.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·威尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN120022352A publication Critical patent/CN120022352A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202510050400.1A 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法 Pending CN120022352A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
CN201980069480.8A CN113038965B (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980069480.8A Division CN113038965B (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Publications (1)

Publication Number Publication Date
CN120022352A true CN120022352A (zh) 2025-05-23

Family

ID=70330587

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510050400.1A Pending CN120022352A (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法
CN201980069480.8A Active CN113038965B (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980069480.8A Active CN113038965B (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Country Status (12)

Country Link
US (2) US12110316B2 (enExample)
EP (1) EP3870212A4 (enExample)
JP (3) JP7426121B2 (enExample)
KR (1) KR20210081372A (enExample)
CN (2) CN120022352A (enExample)
AU (2) AU2019365654B2 (enExample)
BR (1) BR112021007414A2 (enExample)
CA (1) CA3116325A1 (enExample)
IL (2) IL324815A (enExample)
MX (1) MX2021004496A (enExample)
SG (1) SG11202103497WA (enExample)
WO (1) WO2020086400A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081372A (ko) * 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
WO2024118744A2 (en) * 2022-11-30 2024-06-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
US9180167B2 (en) 2011-08-26 2015-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Activators of CXCR3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US9895419B2 (en) * 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210081372A (ko) 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법

Also Published As

Publication number Publication date
EP3870212A1 (en) 2021-09-01
SG11202103497WA (en) 2021-05-28
JP2022512770A (ja) 2022-02-07
US20250002549A1 (en) 2025-01-02
BR112021007414A2 (pt) 2021-08-10
US20210388048A1 (en) 2021-12-16
JP2025172140A (ja) 2025-11-20
IL282431A (en) 2021-06-30
EP3870212A4 (en) 2022-11-16
AU2019365654A1 (en) 2021-05-13
JP7798368B2 (ja) 2026-01-14
CN113038965A (zh) 2021-06-25
IL324815A (en) 2026-01-01
IL282431B2 (en) 2026-04-01
AU2019365654A8 (en) 2021-05-20
WO2020086400A1 (en) 2020-04-30
US12110316B2 (en) 2024-10-08
KR20210081372A (ko) 2021-07-01
JP2024009210A (ja) 2024-01-19
CN113038965B (zh) 2025-02-07
JP7426121B2 (ja) 2024-02-01
AU2025200880A1 (en) 2025-03-06
AU2019365654B2 (en) 2024-11-14
IL282431B1 (en) 2025-12-01
MX2021004496A (es) 2021-06-04
CA3116325A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7798368B2 (ja) Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP2026002845A (ja) 眼の感染症および疾患を処置するための組成物および方法
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
CN102827253A (zh) 一种抑制炎症反应的小分子多肽及其应用
KR101214364B1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
KR101214362B1 (ko) Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
JP7455457B2 (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
WO2015112505A1 (en) Goblet cell replacement therapy
HK40123732A (zh) Cxcr3的可切割激活剂及其使用方法
HK40055610A (en) Cleavable activator of cxcr3 and use method thereof
HK40055610B (zh) Cxcr3的可切割激活剂及其使用方法
WO2010048365A2 (en) Therapeutic peptide bioconjugates
CN103897034B (zh) 一种预防和/或治疗炎症反应的小分子多肽及其应用
EP1862541A1 (en) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
CN110092816B (zh) 预防和治疗纤维化的小分子多肽及其应用
EP2507266A2 (en) TREATMENT OF IgE-MEDIATED DISEASE
JP2019523234A (ja) 眼疾患の処置
HK1240129A1 (en) Method for preventing or treating diabetic retinopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40123732

Country of ref document: HK